T. Rowe Price Funds SICAV European Equity Fund I2 EUR AccumulationRegister to Unlock Ratings |
Performance History | 30/04/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | - | - | - | 12.1 | 5.3 | |
+/-Cat | - | - | - | 0.5 | 0.5 | |
+/-B’mrk | - | - | - | -1.1 | 0.0 | |
Category: Europe Large-Cap Blend Equity | ||||||
Category Benchmark: Morningstar DM Eur TME NR EUR |
Key Stats | ||
NAV 02/05/2024 | EUR 12.93 | |
Day Change | -0.12% | |
Morningstar Category™ | Europe Large-Cap Blend Equity | |
ISIN | LU2483479882 | |
Fund Size (Mil) 30/04/2024 | EUR 89.04 | |
Share Class Size (Mil) 30/04/2024 | EUR 0.01 | |
Max Initial Charge | - | |
Ongoing Charge 01/02/2024 | 0.64% |
Investment Objective: T. Rowe Price Funds SICAV European Equity Fund I2 EUR Accumulation |
To increase the value of its shares, over the long term, through growth in the value of its investments. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Tobias Mueller 01/07/2020 | ||
Inception Date 20/06/2022 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI Europe NR EUR | Morningstar DM Eur TME NR EUR |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for T. Rowe Price Funds SICAV European Equity Fund I2 EUR Accumulation | 31/03/2024 |
|
|
Top 5 Holdings | Sector | % |
Novo Nordisk A/S Class B | Healthcare | 5.56 |
ASML Holding NV | Technology | 5.28 |
SAP SE | Technology | 3.71 |
AstraZeneca PLC | Healthcare | 3.25 |
Siemens AG | Industrials | 3.00 |
Increase Decrease New since last portfolio | ||
T. Rowe Price Funds SICAV European Equity Fund I2 EUR Accumulation |